Abstracts Archive - Page 279 of 2425 - ACR Meeting Abstracts

Abstract Number: 1715 • ACR Convergence 2023
Androgen Treatment Exhibits a Protective Role Against Focal Erosions in TNF-Induced Inflammatory Arthritis in Mice
Kiana Chen¹, Adelaide Weidner², Olga Astapova², Edward Schwarz² and Homaira Rahimi², ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic joint inflammation and bone erosion and is female predominant. The TNF-transgenic (TNF-Tg) murine model of RA develops…
Abstract Number: 1610 • ACR Convergence 2023
Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial
Michael Gendreau¹, Andrea Chadwick², Lance McCracken³, David Williams⁴, Daniel Clauw⁵, Juan Luciano⁶, Yifei Dai⁷, Nicolette Vega⁸, Zunera Ghalib⁸, Kristen Guthrie⁸, Allison Kraus⁸, Michael Rosenbluth⁸, Jennifer Zomnir⁹, Dana Reddy¹⁰ and Lesley arnold¹¹, ¹Gendreau Consulting, LLC, Poway, CA, ²Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, ³Department of Psychology, Uppsala University, Uppsala, Sweden, ⁴Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, ⁷Swing Therapeutics, Gainesville, FL, ⁸Swing Therapeutics, San Francisco, CA, ⁹DelRicht Resesarch, Mckinney, TX, ¹⁰Curavit, Scarsdale, NY, ¹¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH
Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…
Abstract Number: 1679 • ACR Convergence 2023
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Kazuhiro Yokota¹, Yoshimi Aizaki², Takuma Tsuzuki Wada¹, Hiroshi Kajiyama¹, Yasuto Araki², Hiroaki Yazawa², Yuji Akiyama² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: We have previously demonstrated that a combination of TNF-a and IL-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in…
Abstract Number: 1596 • ACR Convergence 2023
A Cell and Transcriptomic Atlas of the Infrapatellar Fat Pad from Patients with Knee Osteoarthritis: Identification of an Obesity-Associated Transcriptomic Signature
Hayley Peters¹, Pratibha Potla¹, Jason Rockel¹, Keemo Delos Santos¹, Shabana Vohra¹, starlee lively², Kim Perry³, Anthony Perruccio¹, Nizar Mahomed⁴, Raja Rampersaud¹, Rajiv Gandhi⁵ and Mohit Kapoor⁶, ¹Schroeder Arthritis Institute, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁴Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Orthopaedics, Department of Surgery, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (KOA) is the most common form of arthritis that affects multiple knee joint tissues. The infrapatellar fat pad is the largest fat…
Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Jinoos Yazdany² and Maria Dall'Era³, ¹University of California San Francisco, San Rafael, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…
Abstract Number: 0991 • ACR Convergence 2023
Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database
Dongxing Xie¹, Qiao Jiang², Yuqing Wang², Huizhong Long², Hu Chen³, Jie Wei⁴, Xiaoxiao Li⁵, Haibo Wang⁶, Chao Zeng⁷ and Guanghua Lei⁷, ¹Xiangya Hospital, Central South University, Changsha, China, ²Xiangya Hospital, Changsha, China, ³Tibet Autonomous Region People’s Hospital, Lhasa, China, ⁴Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁵Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ⁶China Standard Medical Information Research Center, Shenzhen, China, ⁷Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: For end-stage inflammatory arthritis (IA) including rheumatoid arthritis (RA) and spondyloarthritis (SpA), joint arthroplasty is the only treatment option, but is considered to be…
Abstract Number: 0963 • ACR Convergence 2023
Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis
Maithri Aspari¹, Josephine Geertsen Keller-Socin¹, Stinne Greisen², Esben Naeser³, Klaus Soendergaard⁴, Birgitta R Knudsen⁵, Voon Ong⁶, Christopher Denton⁷, David Abraham⁷ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University/Aarhus University Hospital, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Institute for molecular Biology, Aarhus University, Aarhus, Denmark, ⁶UCL Medical School Royal Free Campus, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: The presence of autoantibodies, especially directed towards topoisomerase I (ATA), in diffuse cutaneous Systemic Sclerosis (dcSSc) is known to be associated with severe clinical…
Abstract Number: 1228 • ACR Convergence 2023
Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Caterina Matucci-Cerinic¹, helene Palluy², Sulaiman Al-Mayouf³, Paul Brogan⁴, Luca Cantarini⁵, Ahmet Gul⁶, Ozgur Kasapcopur⁷, Jasmin B. Kuemmerle-Deschner⁸, Seza Ozen⁹, david saadoun¹⁰, Farhad Shahram¹¹, Francesca Bovis¹², Eugenia mosci¹³, Nicolino Ruperto¹⁴, Marco Gattorno¹⁵ and Isabelle Kone-Paut¹⁶, ¹DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, ²Pediatric rheumatology and CEREMAIA, Bicêtre hospital, APHP, University of Paris Saclay, Paris, France, ³King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ⁴UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁸med.uni-tuebingen, Tübingen, Germany, ⁹Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁰Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire, F-75013, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière., Neuilly sur Seine, France, ¹¹Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, ¹²Dept of Health Sciences (DISSAL), University of Genoa, Genova, Italy, ¹³UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ¹⁵UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France
Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…
Abstract Number: 1711 • ACR Convergence 2023
CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert⁴, Andrea La Bella⁵, Susan Shenoi⁶, Joyce Hui-Yuen⁷, Betsy Barnes⁸ and Jessica Hamerman², ¹Seattle Children's Hospital/University of Washington, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Cohen Children's Medical Center, Queens, NY, ⁶Seattle Childrens Hospital, Mercer Island, WA, ⁷Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ⁸Northwell Health, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. MAS is characterized by a dysfunctional hyperinflammatory response in which there is…
Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 1713 • ACR Convergence 2023
Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model
Elisa Dalix¹, Mathieu Maalouf¹, Robin Caire², Guillaume Courbon¹, Virginie Dumas³, Sylvie Peyroche¹, Marie-Thérèse Linossier¹, Mireille Thomas¹, Charles-Antoine Arthaud¹, Arnaud Vanden-Bossche¹ and Hubert Marotte⁴, ¹Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy, ³Laboratory of Tribology and Systems Dynamics, Ecole Nationale d'Ingénieurs de Saint Etienne, Ecole Centrale de Lyon, University of Lyon, Saint-Etienne, France, ⁴CHU Saint-Etienne, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: 1616 • ACR Convergence 2023
Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Joshua Skydel¹, Reshma Ramachandran², Sakinah Suttiratana², Joseph Ross², Joshua Wallach³ and Christopher Burns⁴, ¹Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Yale University, New Haven, CT, ³Emory University, Atlanta, GA, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Clinical trials of systemic lupus erythematosus (SLE) therapies have increased over the last decade, driven by evolving knowledge of targetable pathways. However, these trials…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…
Abstract Number: 1239 • ACR Convergence 2023
Clinical Manifestations and Management of Takayasu Arteritis: A Multicenter Pediatric Cohort
Ana Luiza Altaffer¹, Kristina Ciaglia², Elizabeth Sloan³ and Marietta De Guzman⁴, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴Baylor College of Medicine, Houston, TX
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].